.

The National Agency for Food and Drug Administration and Control (NAFDAC) 5+5 policy is driving increased investment in local pharmaceutical manufacturing, with companies that previously relied heavily on imported medicines now establishing production facilities or exploring contract manufacturing arrangements in Nigeria.
The Executive Secretary of the Pharmaceutical Manufacturing Group of the Manufacturers Association of Nigeria (PMG-MAN), Pharm. Frank Mounemeh, disclosed this in an exclusive interview with Pharmanewsonline, ahead of the Nigeria Pharma Manufacturers Expo.
He said the policy had demonstrated the transformative power of well-designed government intervention in strengthening local pharmaceutical manufacturing, while commending the Director-General of NAFDAC for maintaining a firm position on its implementation.
He stressed that developing a policy was only one part of the process, while faithful implementation was equally important.
The 5+5 policy requires companies holding market authorisations for products that can be manufactured locally to either establish manufacturing capacity in Nigeria or demonstrate arrangements for contract manufacturing within the country.
The policy, he said, had begun to change the behaviour of companies operating in the Nigerian pharmaceutical market, with firms that had held market authorisations for many years now establishing manufacturing facilities locally. Existing manufacturers are also positioning their facilities to undertake contract manufacturing for companies that hold market authorisations but can no longer simply rely on importing the products.
Describing the development as a practical demonstration of how effective government policy could stimulate investment in local pharmaceutical manufacturing, Muonemeh said, “When people ask me what government should prioritise, whether it is access to finance or policy, I always say that with the right policy, everything will fall into place.”
He added that the 5+5 policy had created an environment in which companies were compelled to align their business strategies with the government’s objective of increasing local production. “With the right policy, people are not even asking about funding. They have no choice but to align, look for the funds and get it done,” he said.
The pharmaceutical industry, he noted, was undergoing a transition towards greater self-sufficiency, with local manufacturers increasingly producing medicines and pharmaceutical products that were previously imported. He cited the growth in local production of beta-lactam medicines as an example, saying Nigeria now has close to 10 beta-lactam manufacturing facilities.
The development, he explained, was partly linked to gaps created by the exit of some multinational pharmaceutical companies from the Nigerian market. Although their departure created challenges, it also opened opportunities for local manufacturers to produce medicines previously supplied by the companies.
“With the exit, companies now started focusing on that gap,” he said, adding that the development had encouraged local manufacturers to produce essential medicines that might otherwise have remained dependent on imports.
The industry is also beginning to explore more sophisticated areas of production, including molecules that local manufacturers would not have considered producing a decade ago, as well as opportunities in biosimilar products. However, the broader success of local pharmaceutical manufacturing, he stressed, would depend on consistency in government policies and effective implementation.
He cited the presidential executive order introduced to support local pharmaceutical manufacturing as another potentially impactful policy whose benefits could be weakened by implementation challenges.
Manufacturers, he explained, have experienced difficulties arising from inconsistencies in customs and trade platforms, sometimes resulting in companies paying charges they were not supposed to pay.
“These are all things that add to the cost of production,” he said. Port congestion, delays in clearing pharmaceutical inputs and high energy costs were also identified as significant challenges confronting manufacturers.
He disclosed that energy, accounts for as much as 40 per cent of production costs, compared with significantly lower costs in countries such as India and China. “All these costs add up to the product that comes out of a factory because, trust me, who is going to pay for that cost is the patient,” he added.
He therefore called for greater policy consistency and faithful implementation of government interventions aimed at supporting local pharmaceutical production. “A policy can be well thought out, well written in black and white, but then execution is flawed,” he said, arguing that effective implementation was critical to translating government policies into tangible benefits for manufacturers and patients.
He also called for the extension of the presidential executive order by another two years to allow the relevant policies and implementation mechanisms to stabilise, saying a predictable policy environment would give manufacturers greater confidence to invest in production facilities and expand local capacity.
The PMG-MAN executive secretary said the industry was also looking beyond Nigeria, with regional manufacturing and pharmaceutical sovereignty becoming increasingly important. Strengthening local manufacturing, he explained, was the foundation for expanding Nigeria’s pharmaceutical manufacturing footprint across West Africa and the wider African market.
The forthcoming Nigeria Pharma Manufacturers Expo, he added, would provide a platform for manufacturers, regulators, investors and other stakeholders to examine opportunities for strengthening local and regional pharmaceutical production, while showcasing technologies and inputs required for local manufacturing.
He stressed that Nigeria’s long-term objective should be to move beyond importing finished pharmaceutical products and take greater ownership of the entire pharmaceutical value chain. Effective government policies, increased local investment and stronger manufacturing capacity, he maintained, would be critical to achieving medicine security and improving access to safe, quality and affordable medicines in Nigeria.





